Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Braga
Clinical trial register · Portugal

Clinical Trials in Braga, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 683 Porto 541 Coimbra 258 Braga 180 Vila Nova de Gaia 108
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche17 Janssen Research & Development, LLC16 AbbVie11 Novartis Pharmaceuticals9 AstraZeneca9
Site location
Lisbon683 Porto541 Coimbra258 Braga180 Vila Nova de Gaia108
All 96 locations
Target enrolment
to

Trials with a site in Braga

180 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Lisbon, Vila Nova de Gaia, Braga, Porto
2026-11-30
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Braga, Lisbon, Porto
2026-08-31
Recruiting
How Wall Squat Exercise Affects Blood Pressure in People With High Blood Pressure and Treated Sleep Apnea (WALLPRESS)
NCT07730879Hypertension, Obstructive Sleep Apnea (OSA)
Aveiro University
Not applicable
20
Braga
2026-07-30
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Braga, Lisbon, Porto
2026-06-30
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Braga, Lisbon
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Braga, Viana do Castelo
2026-05-22
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Alcabideche, Almada, Braga, Lisbon, Porto, Senhora Da Hora, Matosinhos, Vila Nova de Gaia
2026-05-20
Not yet open
Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population
NCT07394556Myopia Progression
Indizen Optical Technologies, S.L.U.
Observational
180
Braga
2026-04
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Braga, Lisbon, Santa Maria da Feira
2026-03-26
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Almada, Braga, Lisbon, Loures
2026-03-23
Not yet open
G8 Screening Tool Validation in Older Adults With Cancer in Portugal
NCT07487298Cancer, Frailty, Aged
Hospital de Braga
Observational
150
Braga
2026-03-20
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Braga, Lisbon
2026-03-12
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Braga, Coimbra, Lisbon, Santa Maria da Feira
2026-03-10
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Almada, Amadora, Braga, Coimbra, Lisbon, Loures, Porto, Setúbal
2026-02-16
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Braga, Porto, Viana do Castelo, Vila Nova de Gaia
2026-02-05
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Braga, Matosinhos Municipality, Porto, Viana do Castelo, Vila Nova de Gaia
2026-01-12
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Guimarães, Loures, Senhora da Hora, Braga, Porto
2025-12-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Braga, Coimbra, Funchal, Guimarães, Lisbon, Matosinhos Municipality, Torres Vedras
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Braga, Lisbon, Porto
2025-11-11
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Braga, Coimbra, Lisbon, Porto
2025-11-07
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Braga, Loures, Porto, Vila Nova de Gaia
2025-10-24
Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
DrugSaccharomyces boulardii
Biocodex
Phase 3
406
Braga, Lisbon
2025-10-22
Recruiting
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
NCT07161258Relapsing Multiple Sclerosis
DrugFenebrutinib
Hoffmann-La Roche
Phase 2
12
Braga, Coimbra
2025-10-06
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Braga, Guimarães, Lisbon, Loures, Porto
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Braga, Guimarães, Lisbon, Loures, Porto, Viana do Castelo
2025-10-01
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
Braga, Coimbra, Viana do Castelo
2025-09-29
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
DrugsZiftomenib·Venclyxto·Ara-C·Venclexta
Kura Oncology, Inc.
Phase 3
1,300
Braga
2025-09-26
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Braga, Porto
2025-08-03
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Braga, Carnaxide, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Ponte de Lima, Riachos, Torres Novas
2025-07-25
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Lisbon, Braga, Porto
2025-07-23
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Almada, Amadora, Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon
2025-07-22
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Torres Vedras, Matosinhos Municipality, Braga, Coimbra, Guimarães, Porto
2025-07-21
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
DrugsCDK4/6i·Trastuzumab deruxtecan
MedSIR
Phase 2
200
Lordelo, Alcabideche, Amadora, Aveiro, Braga, Lisbon, Loures, Porto
2025-06-30
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Braga, Coimbra, Lisbon
2025-06-23
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Braga, Faro, Lisbon, Almada, Funchal
2025-06-09
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon, Porto
2025-06-09
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Almada, Braga, Guimarães, Lisbon, Porto
2025-05-22
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
Almada, Braga, Faro, Loures, Matosinhos Municipality
2025-05-15
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Carnaxide, Vila Nova de Gaia, Aveiro, Braga, Coimbra, Leiria, Setúbal
2025-05-08
Recruiting
Impact of In-Person Versus Online Supervised Multicenter Multicomponent Prenatal Exercise Program on Maternal Physical Activity, Fitness, and Healthy Lifestyle
NCT06954454Pregnant Women Participating in a Supervised Multicomponent Exercise Intervention
Polytechnic University of Santarém
Not applicable
250
Braga, Rio Maior, Santarém
2025-04-24
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Alcabideche, Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto
2025-04-10
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
Braga, Coimbra, Lisbon, Porto
2025-04-08
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-03-17
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
Amadora, Braga
2025-03-05
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Braga, Lisbon, Porto, Coimbra, Faro
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Braga, Guimarães, Lisbon, Porto
2025-02-27
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Guimarães, Lisbon, Loures, Senhora da Hora, Almada, Aveiro, Braga, Porto
2025-02-10
Recruiting
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
NCT06487273Non-cystic Fibrosis Bronchiectasis
Physio-Assist
Not applicable
622
Braga, Creixomil, Porto
2025-02-03
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Almada, Braga, Coimbra, Lisbon, Porto
2025-01-31
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Braga, Coimbra, Lisbon, Portimão, Porto, Senhora da Hora, Vila Nova de Gaia
2025-01-28
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 3
1,046
Braga, Lisbon, Porto
2025-01-27
By invitation
Social-HEROES: Health and Education on Research Opportunities Empower Students and Tackle Inequalities
NCT06993051Overweight, Obesity
University of Minho
Not applicable
478
Braga
2025-01-01
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Braga, Lisbon, Porto
2024-12-26
Recruiting
Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.
NCT05401032BPH, LUTS(Lower Urinary Tract Symptoms)
DrugTamsulosin
Clinical Academic Center (2CA-Braga)
Phase 2
70
Braga
2024-12-20
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2024-12-16
Active, closed
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-12-11
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Braga, Vila Nova de Gaia
2024-12-09
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Braga, Porto
2024-10-29
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Braga, Vila Nova de Gaia
2024-10-18
Active, closed
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
960
Braga, Lisbon, Ponte de Lima
2024-10-15
Active, closed
An At-distance and Online Intervention to Promote Parental Involvement and Self-regulation
NCT07400978Parental Involvement, Self-regulation in Children
University of Minho
Not applicable
150
Braga
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Braga, Lisbon, Loures, Porto
2024-10-04
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Braga, Faro, Lisbon, Porto
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Braga, Coimbra, Lisbon, Porto
2024-09-23
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-09-17
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Guimarães, Lisbon, Braga, Coimbra, Viana do Castelo
2024-09-04
Active, closed
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,000
Aveiro, Braga, Carnaxide, Castelo Branco, Coimbra, Faro, Funchal, Lisbon
2024-08-30
Recruiting
MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis
NCT06592352Multiple Sclerosis, Cognitive Impairment
Clinical Academic Center (2CA-Braga)
Phase 2
64
Braga
2024-08-27
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Braga, Coimbra, Lisbon
2024-08-21
Recruiting
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)
NCT06611592Obsessive-Compulsive Disorder
DrugPramipexole
Clinical Academic Center (2CA-Braga)
Phase 2
48
Braga
2024-08-20
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Braga, Vila Nova de Gaia
2024-08-19
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2
660
Santa Maria da Feira, Senhora da Hora, Braga, Coimbra, Lisbon
2024-07-30
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Braga, Leiria, Lisbon, Loures, Ponta Delgada, Porto, Touguinho
2024-07-25
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
Braga, Torres Vedras
2024-07-23
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Aveiro, Braga, Coimbra, Lisbon, Matosinhos Municipality, Porto, Setúbal, Vila Nova de Gaia
2024-07-11
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Braga, Lisbon, Porto
2024-06-29
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Aveiro, Braga, Lisbon, Vila Nova de Gaia
2024-06-03
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Braga, Lisbon
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Guimarães, Coimbra, Almada, Braga, Guarda, Porto, Vila Nova de Gaia
2024-05-20
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Santa Maria da Feira, Senhora da Hora, Braga, Lisbon
2024-05-13
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Braga, Coimbra, Lisbon, Matosinhos Municipality, Vila Nova de Gaia
2024-05-06
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
510
Almada, Aveiro, Braga, Loures, Seco Portimao Faro, Senhora da Hora
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Braga, Canelas-V.N.Gaia, Carregado, Faro, Lisbon, Loures, Oeiras, Porto
2024-04-27
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Braga, Coimbra, Lisbon, Matosinhos Municipality, Santa Maria da Feira
2024-04-16
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
Braga, Lisbon, Porto
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Braga, Lisbon, Porto
2024-03-13
Recruiting
The NEU-STIM Trial
NCT05942924Infant, Premature, Diseases, Birth, Preterm
Leiden University Medical Center
Not applicable
3,280
Braga
2024-03-11
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Alcabideche, Braga, Coimbra, Vila Nova de Gaia
2024-03-07
Recruiting
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341Alpha1-Antitrypsin Deficiency
DrugFazirsiran
Takeda
Phase 3
50
Braga, Funchal, Porto
2024-03-01
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Braga, Lisbon, Porto
2024-02-20
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide
Pfizer
Phase 3
492
Lisbon, Braga
2024-02-08
By invitation
Exercise Prescription in Cardiac Rehabilitation Mediated by Autonomic Function
NCT07288840Cardiac Rehabilitation, Exercise Therapy, Autonomic Nervous System Imbalance, Treatment Outcomes
Instituto Politécnico de Leiria
Observational
90
Leiria, Braga
2024-01-02
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Braga, Lisbon, Porto
2023-12-31
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Braga, Lisbon, Porto
2023-12-30
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Braga, Lisbon, Matosinhos Municipality
2023-12-27
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga
Merck Sharp & Dohme LLC
Phase 3
1,314
Alcabideche, Vila Nova de Gaia, Braga, Lisbon, Porto
2023-12-18
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Braga, Coimbra, Guimarães, Lisbon, Matosinhos Municipality
2023-12-13
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Braga, Guarda, Lisbon
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Braga, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,109
Lisbon, Braga, Viana do Castelo, Viseu
2023-10-25
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Alcabideche, Lisboa, Amadora, Lisboa, Braga, Lisbon, Loures, Porto, Vila Real
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real
2023-10-05
Active, closed
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Urothelial Carcinoma
DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Braga, Lisbon
2023-09-22
Active, closed
A Mentalization-based Intervention for Children of Parent(s) With Borderline Personality Disorder
NCT06050486Child's Internalizing and Externalizing Problems
University of Minho
Not applicable
8
Braga
2023-09-11
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Braga, Creixomil, Porto
2023-09-07
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Braga, Coimbra, Porto
2023-06-22
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320Episodic Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
315
Braga, Coimbra, Lisbon, Porto
2023-06-08
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol
Gilead Sciences
Phase 3
654
Braga, Guimarães, Lisbon, Matosinhos Municipality
2023-05-08
Recruiting
ITreatOCD: Predicting the Efficacy of Internet-based Cognitive Behavioral Therapy in Obsessive-compulsive Disorder
NCT05906069Obsessive-Compulsive Disorder
Pedro Morgado
Not applicable
120
Braga
2023-05-02
Active, closed
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05704049Relapsed/Refractory Multiple Myeloma
DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab
Sanofi
Phase 2
118
Braga, Lisbon
2023-04-05
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Almada, Braga, Lisbon, Porto, Vila Nova de Gaia
2023-03-29
Recruiting
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971Alpha1-Antitrypsin Deficiency
DrugFazirsiran
Takeda
Phase 3
160
Braga, Funchal, Porto
2023-03-06
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Braga, Lisbon, Vila Nova de Gaia
2023-03-02
Recruiting
The Brain, the Bug, and the Binge: the Interplay Between Binge Drinking, Gut Microbiota, and Brain Functioning
NCT05946083Binge Drinking
University of Minho
Phase 2
82
Braga
2023-02-24
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Braga, Coimbra, Covilha, Guimarães, Lisbon, Porto, Pragal, Santa Maria da Feira
2023-02-15
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Braga, Lisbon, Porto
2023-02-08
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Braga, Guimarães, Lisbon, Viana do Castelo
2023-01-16
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Almada, Amadora, Aveiro, Braga, Carnaxide, Cascais, Coimbra, Guimarães
2022-12-14
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
DrugFinerenone
Bayer
Phase 3
100
Braga, Coimbra, Porto
2022-11-08
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Braga, Lisbon, Porto
2022-10-25
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Loures, Braga, Coimbra, Lisbon, Porto
2022-10-14
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Braga, Lisbon, Porto
2022-09-27
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Almada, Braga, Porto
2022-09-23
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
Braga, Lisbon, Porto
2022-09-20
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Braga, Lisbon, Porto, Vila Real
2022-09-08
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Braga, Lisbon, Senhora da Hora
2022-08-05
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Lisbon, Braga, Porto
2022-07-21
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia
2022-05-30
Active, closed
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703Relapsing-remitting Multiple Sclerosis
DrugsFingolimod·Ocrelizumab
Hoffmann-La Roche
Phase 3
188
Braga, Coimbra, Lisbon
2022-05-19
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Braga, Coimbra, Lisbon, Pragal
2022-05-03
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Braga, Carnaxide, Porto
2022-04-05
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
DrugRusfertide
Protagonist Therapeutics, Inc.
Phase 3
293
Almada, Braga, Lisbon, Porto
2022-04-01
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Braga, Carnaxide, Lisbon, Porto
2022-03-15
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab
BeOne Medicines
Phase 3
799
Braga, Porto, VILA NOVA de GAIA Porto
2022-03-10
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Braga, Lisbon, Coimbra
2022-03-07
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023Frontotemporal Dementia
Denali Therapeutics Inc.
Phase 1/2
85
Braga, Torres Vedras
2022-02-01
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Braga, Coimbra, Leiria, Lisbon, Matosinhos Municipality, Santa Maria da Feira
2021-12-13
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Erbitux·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-12-10
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
600
Almada, Porto Covo, Braga, Coimbra, Porto
2021-12-01
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
282
Braga, Lisbon, Porto
2021-09-23
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Braga, Guarda, Lisbon, Ponte de Lima, Porto
2021-08-30
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Braga, Guimarães, Lisbon, Porto, Senhora da Hora, Vila Real
2021-08-19
Active, closed
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361Multiple Sclerosis
Hoffmann-La Roche
Phase 1
119
Braga, Lisbon, Santa Maria da Feira
2021-08-11
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
712
Braga, Coimbra, Faro, Lisbon
2021-08-05
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsAdagrasib·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Braga, Lisbon, Porto
2021-06-24
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Braga, Lisbon, Porto
2021-05-26
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Senhora Da Hora, Matosinhos, Almada, Aveiro, Braga, Guarda, Guimarães, Lisbon, Porto
2021-04-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
DrugsFenebrutinib·Teriflunomide
Hoffmann-La Roche
Phase 3
746
Braga, Coimbra, Lisbon, Porto, Santa Maria da Feira
2021-03-17
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
DrugsAdagrasib·Taxotere·Docetaxel
Mirati Therapeutics Inc.
Phase 3
453
Almada, Braga, Coimbra, Guimarães, Lisbon, Loures, Porto, Santa Maria da Feira
2021-02-23
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-02-23
Recruiting
Psychological Intervention for Child Mental Health Based on Parental Reflective Functioning to Enhance Positive Parenting
NCT05490745Externalizing Problems, Internalizing Problems
University of Minho
Not applicable
60
Braga
2021-02-04
Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
NCT06601270Spontaneous Coronary Artery Dissection
European Society of Cardiology
Observational
1,500
Amadora, Braga, Evora, Tondela
2021-01-30
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,371
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-01-28
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
769
Braga, Lisbon, Porto
2020-12-03
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
864
Braga, Lisbon
2020-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
DrugsFenebrutinib·Ocrelizumab
Hoffmann-La Roche
Phase 3
985
Braga, Lisbon, Porto
2020-10-26
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Braga, Guimarães, Lisbon, Loures, Porto, Vila Real
2020-10-19
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Braga, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2020-10-08
Recruiting
Maintenance Optimization of the Fully Implanted Venous Catheter
NCT05411666Cancer
Clinical Academic Center (2CA-Braga)
Not applicable
176
Braga
2020-06-30
Active, closed
Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region
NCT04288531Iodine Deficiency, Thyroid, Pregnancy Related, Psychomotor Impairment
University of Minho
Observational
304
Braga
2020-01-10
Active, closed
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877Multiple Sclerosis, Relapsing-Remitting
DrugsPlegridy·Avonex
Biogen
Phase 3
152
Lisbon, Loures, Braga, Coimbra, Porto
2019-10-18
Active, closed
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NCT04006210Parkinson's Disease
NeuroDerm Ltd.
Phase 3
381
Braga, Torres Vedras
2019-09-30
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Braga, Lisbon, Porto
2019-08-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005Multiple Sclerosis, Primary Progressive
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,013
Loures, Almada, Braga, Porto, Torres Vedras
2019-08-12
Active, closed
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308Psoriatic Arthritis
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
964
Vila Nova de Gaia, Ponte de Lima, Aveiro, Braga, Lisbon
2019-03-25
Active, closed
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536Myelodysplastic Syndromes
DrugsEpoetin Alfa·Luspatercept
Celgene
Phase 3
363
Beja, Braga, Lisbon, Porto, Setúbal
2019-01-02
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto, Santa Maria da Feira
2018-12-28
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Braga, Coimbra, Lisbon, Porto
2018-12-24
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Braga, Lisbon, Porto
2018-12-17
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Braga, Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Setúbal, Vila Real
2018-11-28
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Braga, Coimbra, Guimarães, Portimão, Porto, Santa Maria da Feira
2018-04-13
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Braga, Coimbra, Lisbon, Porto
2017-12-18
Active, closed
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03319667Plasma Cell Myeloma
DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide
Sanofi
Phase 3
475
Braga, Coimbra, Lisbon, Porto
2017-12-07
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 3
443
Braga, Porto
2017-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
DrugUpadacitinib
AbbVie
Phase 3
950
Guimarães, Santa Maria DA Feira, Almada, Braga, Lisbon, Porto, Viana do Castelo
2017-01-31
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Lisbon, Vila Nova de Gaia, Braga, Porto, Viana do Castelo
2015-12-01
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Braga, Porto
2014-08-28
Active, closed
Psoriasis Longitudinal Assessment and Registry
NCT00508547Psoriasis
Janssen Scientific Affairs, LLC
Observational
20,167
Braga, Lisbon, Porto, Vila Nova de Gaia
2007-06-21
Rows per page Showing 1–180 of 180
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/braga

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 180 of those studies with a site in Braga.

How many clinical trials are recruiting in Braga?

89 of the 180 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 4 have not yet opened recruitment, 82 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Braga), 180 studies
PhaseStudiesRecruitingShare
Phase 31245668.9%
Phase 2191410.6%
Not applicable1075.6%
Observational1025.6%
Phase 2/31075.6%
Phase 1311.7%
Phase 1/2321.7%
Phase 4100.6%

Most active sponsors

Lead sponsors with the most studies (Braga)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche176
Janssen Research & Development, LLC1611
AbbVie114
AstraZeneca94
Novartis Pharmaceuticals94
Boehringer Ingelheim75
Merck Sharp & Dohme LLC72
Sanofi71
Eli Lilly and Company66
University of Minho62
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.